The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Alternative Medicine
- Artificial Intelligence
- Atlas Shrugged
- Ayn Rand
- Basic Income Guarantee
- Big Tech
- Black Lives Matter
- Boca Chica Texas
- Casino Affiliate
- Cbd Oil
- Chess Engines
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Designer Babies
- Donald Trump
- Elon Musk
- Ethical Egoism
- Eugenic Concepts
- Fake News
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom of Speech
- Gene Medicine
- Genetic Engineering
- Germ Warfare
- Golden Rule
- Government Oppression
- High Seas
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Longevity
- Immortality Medicine
- Intentional Communities
- Jordan Peterson
- Las Vegas
- Life Extension
- Marie Byrd Land
- Mars Colonization
- Mars Colony
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- National Vanguard
- New Utopia
- Online Casino
- Personal Empowerment
- Political Correctness
- Politically Incorrect
- Post Human
- Post Humanism
- Private Islands
- Proud Boys
- Quantum Computing
- Quantum Physics
- Resource Based Economy
- Ron Paul
- Second Amendment
- Second Amendment
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tor Browser
- Transhuman News
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Zeitgeist Movement
The Evolutionary Perspective
Monthly Archives: November 2020
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Sona Nanotech Inc. and Encourages Investors with Losses of…
Posted: November 29, 2020 at 6:43 am
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sona Nanotech Inc. (Sona or the Company) (OTC: SNANF) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sona announced on October 29, 2020, that the FDA had denied its request for an emergency use authorization to market its rapid COVID-19 antigen test in the United States. The Companys shares fell 48% on the same day. Then on November 25, 2020, the Company announced the withdrawal of an Interim Order authorization from Health Canada for the marketing of its rapid, COVID-19 antigen test in order to obtain more clinical data to augment its submission. Based on this news, shares of Sona fell by more than 67% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.schallfirm.com, or by email at email@example.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Continue reading here:
Sona Nanotech Withdraws Health Canada Application For COVID-19 Test Due To Feedback From Regulator – The Deep Dive
Posted: at 6:43 am
In what is a major blow to shareholders of Sona Nanotech (CSE: SONA), the company this afternoon announced that it has withdrawn its rapid COVID-19 antigen application from Health Canada based on feedback it has received from the regulatory agency. The move is being conducted in order to obtain more clinical data to augment its submission.
While the application for approval has been withdrawn, the company indicate that it will continue to pursue approval of the test from the agency, which is a nasal swab-type test. Sona is also reportedly continuing to validate its saliva-based version of the rapid test. Now, the company will be looking to conduct a large scale trial for this saliva-based test.
Despite withdrawing its application for an interim order authorization from Health Canada for the marketing of its test, the company continued to state within the news release that its COVID-19 antigen test offers results within 15 minutes. The company also reiterated that testing has shown an agreement with RT-PCR tests 85% of the time, along with 96% sensitivity.
Commenting on the withdrawn application, President and chief scientific officer Darren Rowles stated, The regulatory approval path for antigen tests is new with evolving guidelines and Sonas test is unique, creating a challenging environment for test developers and regulators alike. He then followed up that statement by indicating the company is committed to obtaining the data required.
A timeframe for the required data collection to proceed with Health Canada authorizations was not provided by the company. The company has indicated that it intends to resubmit its application as quickly as possible
Sona Nanotech last traded at $3.11 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dives stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
Posted: at 6:43 am
A company has been launched in Hull to take an award-winning long-lasting antimicrobial solution aimed at easing the Covid crisis to the UK market.
As protective pandemic measures remain at the highest level with the second lockdown coming to an end, Cicada is ready to roll from a new Sutton Fields base.
A subsidiary of Pocklington-headquartered automotive industry specialist Duracare, it has been established after the product - part of a package of nanotechnology solutions for paint and interiors - was found to have the ability to create safe high-touch areas.
Now Cicada has formed a partnership with the Welsh-based distributor, with serious investment to consult, advise and apply in various settings, from offices and care homes to schools and nurseries.
Noel Parkinson, director, said: The coating forms a nano-scale layer of glass over the surface of base materials which not only makes them easier to clean as it repels liquid and dirt, it also provides a protective antimicrobial layer to constantly kill viruses, bacteria, moulds and fungi. The microbe is physically killed as the surface punctures the cells outer wall, rendering it inactive. This product provides a proven minimum 12-month antimicrobial protection to all treated areas.
The active ingredient comes from a break-through by Liquid Guard Technology, which saw it pick up a German innovation award last year.
Dermatologically tested, it has also been classed as excellent in terms of compatibility with skin contact, Mr Parkinson said.
An early adopter of the technology is Hull Collegiate School, where the leadership team felt the extra level of protection for all touch surfaces had potential to reduce the threat of infections.
Deputy head Chris Wainman said: In line with Government guidance we want to provide pupils with ongoing access to their education in school, within the safest possible environment. Local Covid-19 cases were at the highest levels in the UK, therefore the health and safety of pupils and staff has been at the forefront of our decision. The use of this treatment gives us confidence that we are taking every possible measure to protect pupils and their families.
Traditional disinfection and cleaning methods have limitations in busy areas such as walkways, entrances, dining and washroom facilities. Surface disinfection only kills the bacteria and viruses that are present on surfaces at that moment in time. Once the sanitising process is complete and people return to the area, they bring with them transient microbes, that are then immediately deposited through hand-surface-hand contact to any surface touched, and therefore continue the spread of infections.
A team of three has been established, with environments cleared for a six hour period to facilitate the procedure.
See the rest here:
Posted: at 6:43 am
Published on November 28, 2020
The size of one nano particle is one billionth of a metre, which is approximately thousand times smaller than the width of human hair. Making new things at this incredibly small scale is called Nanotechnology, and is the most exciting and fast-moving area of science today. By re-arranging the atoms of an object, the scientists can make new nanomaterials with new properties. Such materials can be stronger, lighter or different in colour than their parent material. Their properties too change according to their size and this is the magic of nanotechnology. Even as rapid advancement has been made in the field globally, a few Indian companies too have been functioning in the domain, empowering different sectors significantly. Lets take a look at 5 Indian nanotechnology companies that are doing it right.
Ad-Nano Technologies:Based in Karnatakas Shivamogga, Ad-Nano technologies is into manufacturing of nanomaterials, and further deals in Research and Development programmes to provide innovative systems by introducing nanotechnology in it. Some of its sought-after products include Carbon Nanotubes and its variants, Metal Oxide Nanoparticles and graphene, along with its variants. Apart from these, the company also provides Nanomaterials Analytical Services. They boast of offering accurate analysis related to nano materials characterisation. Some of its flagship products, launched in the wake of Covid-19, are Cowin guard floor, Cowin guard curtains and Cowin guard material sheet for PPE kits.
Nanomatrix Materials:One of the latest entrants in the segment, Nanomatrix Materials is among the few Indian companies that work on manufacturing of graphene and its integration into application and value added propositions from across different industries. The Jaipur-based startup, founded by a group of experts from the graphite industry,is a nano and advanced material manufacturer which uses proprietary disruptive graphene technology and its integration into smart publications. The company partners with industry players in the domains such as filtration, polymer, construction, energy and textiles to solve their unique challenges through the power of Nanotechnology. They recently developed a graphene-silver membrane that not just prevents but kills coronavirus within seconds.
Bee Chems:Founded in 1972, Bee Chems claims to be the first Indian company to manufacture colloidal silica and make active desiccants & eco-friendly silica gel. According to the company, Nano Chemistry and silicates were its founding pillars. They are into production of grades and varieties of all nano and colloidal inorganic sols and silicates such as colloidal silica, nano silica, colloidal alumina, titania, zirconia sols & sodium, potassium, lithium silicates and calcium silicates. The company is based in Kanpur city of Uttar Pradesh.
E-Spin Nanotech:The company claims to be a one-stop destination for Nanofiber Technology and its commercial product development. Founded almost a decade ago, E-Spin Nanotech is one of Indias leading high-tech enterprises for manufacturing high quality and cost-effective multi-functional nanofibers. It boasts of revolutionizing the prospects of nanofibers with a series of advanced electrospinning units specifically designed to meet sophisticated prerequisites of research organization and industries. Besides, they also provide nanotechnology consultancy services. The company was incubated by Startup Incubation and Innovation Centre at IIT Kanpur.
Originally posted here:
In-Depth Research on Aerospace Nanotechnology Market (impact of COVID-19) with Top Players: Airbus , Glonatech , Flight Shield , Lockheed Martin, and…
Posted: at 6:43 am
This report studies the Aerospace Nanotechnology market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Aerospace Nanotechnology market analysis segmented by companies, region, type and applications in the report.
The key players covered in this study Airbus
tripleO Performance Solution
Other prominent vendors
Market segment by Type, the product can be split intoType 1
Market segment by Application, split intoApplication 1
Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America
Table of Contents: Aerospace Nanotechnology Market
Chapter 1: Overview of Aerospace Nanotechnology Market
Chapter 2: Global Market Status and Forecast by Regions
Chapter 3: Global Market Status and Forecast by Types
Chapter 4: Global Market Status and Forecast by Downstream Industry
Chapter 5: Market Driving Factor Analysis
Chapter 6: Market Competition Status by Major Manufacturers
Chapter 7: Major Manufacturers Introduction and Market Data
Chapter 8: Upstream and Downstream Market Analysis
Chapter 9: Cost and Gross Margin Analysis
Chapter 10: Marketing Status Analysis
Chapter 11: Market Report Conclusion
Chapter 12: Research Methodology and Reference
Reports And Marketsis part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.
Manager Partner Relations & International Marketing
Ph: +1-352-353-0818 (Us)
The rest is here:
CNTs Conductive Paste Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of…
Posted: at 6:43 am
Global CNTs Conductive Paste Industry Research Report Provides Detailed Insight Covering all Important Parameters Including Development Trends, Challenges, Opportunities, Key Insights and Competitive Analysis of CNTs Conductive Paste Market.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CNTs Conductive Paste market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CNTs Conductive Paste market in terms of both revenue and volume.
Get Exclusive Free Sample Report on CNTs Conductive Paste Market is available at https://inforgrowth.com/sample-request/6383434/cnts-conductive-paste-market
Impact of COVID-19: CNTs Conductive Paste Market report analyses the impact of Coronavirus (COVID-19) on the CNTs Conductive Paste industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CNTs Conductive Paste market in 2020
COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.
Get the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6383434/cnts-conductive-paste-market
Top 10 leading companies in the global CNTs Conductive Paste market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and CNTs Conductive Paste products and services
Top Players Listed in the CNTs Conductive Paste Market Report areMiller-Stephenson, Meijo Nano Carbon, Novarials, Shenzhen Dynanonic, Shenzhen Jinbaina Nanotechnology, Cnano Technology, Susnzk, Shenzhen Nanotech Port.
Based on type, The report split into Ultra-high Purity Conductive Paste, Conventional Purity Conductive Paste, Composite Conductor Conductive Paste.
Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Power lithium battery, Digital battery, Silicon-based anode, .
Get Special Discount Up To 50%, https://inforgrowth.com/discount/6383434/cnts-conductive-paste-market
The study objectives of this report are:
FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898
Read the original post:
Comprehensive Report on Protective Implant Coating Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Nanogate, Nanomech,…
Posted: at 6:43 am
Protective Implant Coating Marketresearch report is the new statistical data source added byA2Z Market Research.
Protective Implant Coating Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.
Protective Implant Coating Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.
Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:
Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
Top Key Players Profiled in this report are:
Nanogate, Nanomech, Nanovere Technologies, CIMA Nanotech, Nanophase Technologies Corporation, Nanofilm, Surfix, P2I Ltd, AdMat Innovations, Integran Technologies, Buhler.
The key questions answered in this report:
Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Protective Implant Coating market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Protective Implant Coating markets trajectory between forecast periods.
Global Protective Implant Coating Market Segmentation:
Market Segmentation: By Type
Market Segmentation: By Application
Dental ImplantBone ImplantOrgan ImplantOthers
Get up to 30% Discount on this Premium Report @:
Regions Covered in the Global Protective Implant Coating Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)
The cost analysis of the Global Protective Implant Coating Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.
The report provides insights on the following pointers:
Market Penetration:Comprehensive information on the product portfolios of the top players in the Protective Implant Coating market.
Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Protective Implant Coating market.
Table of Contents
Global Protective Implant Coating Market Research Report 2020 2026
Chapter 1 Protective Implant Coating Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
Chapter 11 Market Effect Factors Analysis
Chapter 12 Global Protective Implant Coating Market Forecast
Buy Exclusive Report @:
If you have any special requirements, please let us know and we will offer you the report as you want.
About A2Z Market Research:
The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.
Our Research Analyst Provides business insights and market research reports for large and small businesses.
The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.
1887 WHITNEY MESA DR HENDERSON, NV 89014
+1 775 237 4147
Go here to read the rest:
Posted: at 6:42 am
Retired MMA fighters Ian McCall and Dean Lister (from left to right, top right corner) attended a ... [+] plant medicine ceremony where they drank tea containing up to five grams of magic mushrooms, in this still image from a recent segment of HBO's Real Sports with Bryant Gumbel.
A segment on a recent episode of HBOs Real Sports With Bryant Gumbel begins with former NHL player Daniel Carcillo describing his plan to kill himself. Hes one of four athletes in the episode who after retiring from full-contact sports had been both physically and mentally traumatized by the long-term effects of repeated concussions, and has now found relief with psychedelics.
Carcillo, former NFL player Kerry Rhodes, and former UFC fighters Ian McCall and Dean Lister are part of a growing movement of people using plant medicines like ayahuasca and magic mushrooms to help heal post-traumatic stress disorder and the symptoms of brain trauma.
On the outside, it seemed like Carcillo, a two-time Stanley Cup winner had it all: a wife and children, a comfortable home, and a successful career in the worlds premiere professional hockey league. But truthfully, Carcillowhose on-ice reputation earned him the nickname car bombtold correspondent David Scott hed never felt more dead inside.
Pierre-Edouard Bellemare of the Philadelphia Flyers fights with Daniel Carcillo of the Chicago ... [+] Blackhawks on March 25, 2015 in Philadelphia, Pennsylvania. Carcillo earned the nickname "car bomb" for his tendency to get in fights.
Depression is just one of multiple symptoms associated with chronic traumatic encephalopathy, or CTE, a condition of the brain that is associated with repeated blows to the head. Other symptoms include memory loss, confusion, personality changes, and erratic behavior. A definitive diagnosis can only be made in an autopsy, but a 2017 study showed CTE was found in 99 percent of former NFL players and 91 percent of college football players studied.
Diagnosed with seven concussions throughout his 12-year professional hockey career Carcillo says he likely experienced hundreds more, and went down multiple avenues trying to improve his mental health. After trying psychotherapy and different SSRIs, he opted for something outside Western medicines realm of treatment: ayahuasca, a South American brew revered by Indigenous cultures as a powerful medicine and containing the psychedelic compound N,N-Dimethyltryptamine, or DMT.
Im just trying to look for more peace of mind, less suffering, he says to the cameras from the Peruvian jungle before attending the ceremony. Four hours later, he emerges feeling changed, and calls it the most amazing experience of his life.
Months later when HBOs production team visits Carcillo, he says hes experiencing little to no depression and anxiety, while symptoms including slurred speech, headaches, head pressure, memory issues, concentration, and insomniaare all completely gone.
I didnt see him smile for years, says his wife, Ela. With her husband still symptom-free after five months, she asks Scott, how can you not believe this stuff works?
While the results of Carcillos experience are truly astonishing, Scott says its the way these experiences pair up with existing clinical research that truly makes the story.
Bilal Powell of the New York Jets is tackled by Kerry Rhodes of the Arizona Cardinals on December 2, ... [+] 2012. Rhodes, now retired, experienced many concussions throughout his career and went to Costa Rica to drink ayahuasca to help overcome the symptoms of brain trauma.
Athletes started emerging as potential patients who could benefit from these therapies, he says by phone from the Bronx. Their experience lines up with emerging science. For treatment-resistance depression and PTSD, these drugs can provide relief for a lot of people. Maybe not for everyone, and maybe its not going to fix everything, but better is better, and these guys hadnt found better in anything else.
Whats more, Scott suggests that had the federal government not shut down psychedelic research, which was in full swing before the war on drugs began, generations of people suffering from depression, addiction, and trauma could have been helped.
The segment directed by Jordan Kronick also features psychedelic researcher Dr. Robin Carhart-Harris of the Imperial College London. He says a single dose of psilocybin has been shown to produce enduring results in patients suffering from a multitude of conditions that run the gamut, from depression and anxiety to obsessive compulsive disorder and more.
When former NFL player Rhodes is featured, he gets emotional when recalling his first ayahuasca ceremony in Costa Rica. Like Carcillo, Rhodes says the experience changed him, eliminating his headaches and pain, bringing back his memory, and even removing his fear around CTE, leading to huge improvements in quality of life.
I hear stories like that a lot, but Im not surprised because thats how these drugs have been used for thousands of years, says Rick Doblin, the founder of the non-profit Multidisciplinary Association for Psychedelic Studies, or MAPS. Doblin describes what happened in America after the U.S. government shut down psychedelic research as an incredible exercise in cultural amnesia, and advocates for increased study of psychedelics through his organization.
McCall fought in the UFC and other professional MMA leagues for 15 years before finally tapping out. Injury after injury had left him snorting opiate painkillers including fentanyl on a regular basis, turning him into a self-described monster. Experimenting with psychedelics, he says, helped cure him of his addiction and suicidal thoughts.
Yushin Okami (white shorts) on the offensive against Dean Lister (grey/blue shorts) during UFC 92 at ... [+] MGM Grand Garden Arena on December 27, 2008. Lister, revered among grapplers as the godfather of modern leg locks, was defeated in what ended up being his last fight in the UFC.
Today, he is committed to helping improve the mental health of other former fighters by showing them how life-altering regular group experiences with psychedelic medicines can be.
Fighters are good people, McCall says, but theyre tormented. The Real Sports segment takes viewers inside a private ceremony in which a group of fighters including grappler and former UFC star Lister are guided through a psilocybin trip by a shaman.
Like any longtime mixed martial artist, Lister has experienced his fair share of head trauma, and describes the symptoms associated with repeated concussions like being stuck in a prison cell in your own mind. Before taking five grams of mushrooms (with McCall seated to his right), Lister was struggling with alcoholism, drinking up to 20 beers a day and taking Xanax every night.
During the deep journey (the only kind afforded to anyone who consumes five grams, or a heros dose, at one time) Lester experiences the kind of near-death hallucination only psychedelic travellers will be familiar with, and says to himself, If I wake up, Im going to do things different. Since the experience, hes steered clear of all drugs and alcohol.
Its so common with psychedelics, that sense of something really serious happening, maybe even death, says Carhart-Harris. The way it turns around, where people realize, oh, Im not actually dyingthats where the shift happens. Its like survivor euphoria: oh, I do have that second chance.
Continue reading here:
How his lifelong psychedelic journey may lead to the legalization of MDMA – The Jewish News of Northern California
Posted: at 6:42 am
When Rick Doblin was in his early 20s, he had a dream in which he was escorted back in time to witness a Holocaust survivors narrow escape from the Nazis.
In his mind, Doblin traveled to Eastern Europe to witness thousands of Jews lined up alongside a mass grave as the gunners open fire, toppling the bodies into the earth. The man spends three days alive underground before emerging and fleeing to the woods, where he survives the war in hiding.
The man then tells Doblin that he survived this horror only to deliver a message that Doblin should devote his life to promoting psychedelics as a cure for human ills and an insurance policy against another Holocaust. Then he expires.
Doblin took the advice to heart. For much of the next four decades, he waged an often frustrating battle to get public health authorities to recognize the value of psychedelics, the perception-shifting compounds popularized in the 1960s that have been a source of both fear and fascination ever since.
Ive always felt that the response to the Holocaust is helping people realize our common humanity, Doblin said. And that there are many ways to do that, and psychedelic mystical experiences are one of the ways. And so I felt like what Im doing is to try to prevent another Holocaust and that thats the deepest motivation.
In the United States, research on these chemicals has been banned since the 1960s because, in the governments judgment, they have no recognized medical value and a high potential for abuse. But a growing body of research has shown their efficacy for a range of mental illnesses that have proven resistant to other treatments, including post-traumatic stress disorder, addiction, depression and anxiety. Research underway at Johns Hopkins and New York University is also investigating whether psychedelics can be of use in a wider array of applications, including one study on whether the drugs can induce spiritual experiences among religious clergy.
Doblin has funded some of this research as the founder of the Multidisciplinary Association for Psychedelic Studies, a nonprofit he runs from his home here in suburban Boston. And after years of effort and $100 million raised, he now stands on the cusp of a major victory.
In late October, Doblin received preliminary results from a MAPS-funded phase 3 study of the effects of MDMA better known as the club drug Ecstasy on PTSD. Phase 3 trials are typically the final hurdle before the Food and Drug Administration authorizes a drug for public use. Those preliminary results showed MDMA surpassed the FDAs threshold for statistical significance in treating PTSD.
A formal scientific paper is due early next year and Doblin expects government authorization for prescription use will eventually follow. If it does, it would be the first time the federal government has ever approved a psychedelic to assist in psychotherapy.
Its enormously satisfying because it was something that Ive basically been devoted to for the last 48 years, Doblin told the Jewish Telegraphic Agency. It was just ecstatic, you could say.
Legalization of medical MDMA would represent the culmination of a journey that Doblin often traces back to his bar mitzvah.
Born in Chicago in 1953, Doblin was raised in suburban Skokie, a heavily Jewish area home to a large number of Holocaust survivors. The family later moved to Winnetka, an affluent suburb where they lived in a house designed by an apprentice of Frank Lloyd Wright that had a tree growing in the middle of it. His father, Morton, was a pediatrician and his mother, Arline, a schoolteacher.
I grew up thinking the whole world was Jewish, Doblin said. That was my education. All my parents friends were Jewish. The neighbors were all Jewish. We went to temple. Youre a little kid, you think your whole world is the universe.
Though his family had arrived in America before the war, the Holocaust loomed large in Doblins childhood imagination. The irrational hatred, the othering of minorities and the potentially lethal consequences terrified him. Psychedelics offered him a way to turn that fear into something useful.
It also showed him a way to invigorate his inner life in a way that Judaism had failed to, a fact that came home to him in dramatic fashion as he lay in bed the morning after his bar mitzvah and was disappointed to discover nothing had changed. This rite of passage that Jewish boys had undergone for centuries had failed to turn him into a man.
I just felt like my bar mitzvah was a massively disappointing rite of passage that didnt engage me at the levels that I needed to be engaged in, that I was hungry for, he said. So four years later, when I first started taking LSD, I was like, this is what my bar mitzvah should have done. This is engaging me at the existential, spiritual, emotional levels that really can produce a rite of passage, that this is what I was missing.
Doblin enrolled at New College in Sarasota, Florida, then an experimental school that he recalls as a four-year bacchanal where students lounged poolside in the nude by day and danced all night under the influence of psychedelics. It took him 16 years to earn his degree.
He first tried LSD in his freshman year. And though the effects were not the full-blown mystical experience many report under the drugs influence, it was enough to convince him that this chemical synthesized in a Swiss laboratory in 1938 held enormous potential for human transformation.
In the first, Id say, 10 LSD trips, what they were doing for me was putting me in touch with my emotions and also helping me think more about kind of this inner energy, and also these intimations of connectivity with the history of evolution, with other people, with nature, he said.
At the time, a community of psychedelic enthusiasts, driven underground by the governments ban on LSD research, was quietly developing methods to harness the drugs power for psychic healing and spiritual growth. Doblin fell in with this crowd, which included Dr. Stanislav Grof, the Czech psychiatrist who had done some of the earliest research with LSD.
As Doblin pursued his ambition of becoming a psychedelic therapist, he undertook various passion projects in Florida, including building a handball court for the college and starting a construction business. In Sarasota, he lived in a fanciful cedar house he built himself as a venue for tripping, including a massage room, a soaring 20-foot ceiling, stained glass panels, floors made of river gravel but no television.
TV, Doblin told the Miami Herald in 1985, causes brain damage.
By the mid-1980s, Doblin had become a nationally recognized evangelist for MDMA, then just emerging into the public consciousness as a trendy new club drug. Around that time, at the urging of a top U.N. official with whom he shared the belief that a global spiritual awakening was the key to world peace, Doblin sent an MDMA sample to Rabbi Zalman Schachter-Shalomi, the New Age rabbi and father of the Jewish Renewal movement.
Schachter-Shalomi was famously interested in psychedelics, having done LSD with Timothy Leary in the 1960s and reporting on the experience to his colleagues. Helater told The Washington Post, anonymously, that MDMA was a delight akin to the Jewish Sabbath. Doblin wound up visiting Schachter-Shalomis Philadelphia synagogue several years later, where he attended Yom Kippur services under the influence of MDMA.
It was amazing, Doblin said. It really opened my heart. MDMA and Yom Kippur go together great.
Doblin established MAPS in 1986, the year after the Drug Enforcement Administration declared MDMA a Schedule I narcotic, the governments most restrictive designation. For most of the next three decades, Doblin waged what seemed at times like a hopeless battle to pry open the door to psychedelic research, even earning a doctorate from the Kennedy School of Government at Harvard to get the skills to confront the government bureaucracy.
He found particularly fertile ground for these efforts in Israel, where he has extensive family ties and where decades of war and terrorism had made PTSD an urgent public health concern. (His great-grandparents house is aTel Aviv landmarkthat is now home to the Heseg Foundation.) MAPS held a conference by the Dead Sea in 1999 in an attempt to push Israeli regulators to approve a study of MDMA for the treatment of PTSD. Among the attendees was Raphael Mechoulam, the legendary Israeli researcher best known for identifying THC, the active ingredient in marijuana.
Israel later became the first country in the world to approve a compassionate use program for MDMA-assisted psychotherapy for PTSD (the United States followed several months later) and provide public support for MDMA research, to the tune of $500,000 approved in February 2019. Israel is now one of just three countries where phase 3 trials are underway. (The United States and Canada are the others.)
Doblin declined to provide specifics about the preliminary results of the phase 3 trials, pending the publication of a formal paper. But preliminary results from phase 2 trials conducted partly in Israel found that out of 107 patients who had suffered from PTSD for an average of nearly 18 years, 68 percent reported no symptoms one year after MDMA-assisted therapy an extraordinary rate of success. Those results led the FDA in 2017 to declare MDMA a breakthrough therapy and to green-light phase 3 trials, which began the following year.
I think that what happens with MDMA, because of its pharmacological profile increased dopamine, serotonin, oxytocin it creates a sense of well-being, said Keren Tzarfaty, a therapist who directs Israeli projects for MAPS. The person is getting regulated and has a very beautiful experience of safety. And from this place, they can look and be with the trauma they have experienced. Then we can help them to process it.
The phase 3 results are landing in an environment newly receptive to these chemicals long demonized as tools of the counterculture.
At Johns Hopkins, a psychedelic research unit has published over 50 peer-reviewed papers investigating not only the potential to treat disease with psychedelics, but also their effects on healthy subjects. Investors are flocking to a nascent psychedelics industry, anticipating a boom similar to the one that accompanied the rise of medical marijuana a decade ago. The Harvard Divinity School is currently hosting a lecture series about psychedelics and the future of religion. And earlier this month, Oregon became the first state to legalize psilocybin, the active ingredient in psychedelic mushrooms, in therapeutic settings. Michael Pollans 2018 book How to Change Your Mind, which surveyed this landscape, topped The New York Times best-seller list.
Doblin is naturally thrilled about this shift in the zeitgeist, one he had no small part in creating. But unlike many proponents of research into formerly forbidden drugs, Doblin is candid that his endgame is broad legalization. In his view, the ideal scenario is a regime called licensed legalization in which the right to use psychedelics is akin to driving a car: After taking the drug in a supervised setting, users are granted a license to use that can be taken away in response to misbehavior.
Doblin predicts a system of this nature could be a reality by 2035, after a decade or so in which controlled therapeutic use accustoms the public to the value of these chemicals. In Doblins ideal world, the system also would allow parents to make private decisions about giving psychedelics to their children.
I think that psychedelics are great for rites of passage, Doblin said. I think that when you are 12, or 13, you are ready for trying to figure out your place in the world. So I think that we would have psychedelic bar and bat mitzvahs.
Rabbi Zac Kamenetz of Berkeley, the founder and CEO of Shefa, a new group that advocates for psychedelic therapies in the Jewish community, says that Doblins twin objectives of healing the wounds of past atrocities and infusing contemporary life with deeper meaning is an echo of the question Rabbi David Hartman posed in his seminal 1982 essayAuschwitz or Sinai.
Rick might not think of himself as a Jewish theologian, and maybe hes not, Kamenetz said. But he happens to be in a position of recasting the question: Is the Jewish agenda for the next 1,000 years going to be in the pain and trauma of Auschwitz, or are we doing to drop anchor and reach back to the moment thats always been the moment, the moment of revelation at Sinai? Do we want to reach into something that is transcendent, that exists within the human mind and heart? And that for Rick and for me is made completely available through the use of psychedelic therapy.
Such ideas, and Doblins fearlessness in promoting them, havent always endeared him to psychedelic researchers, who have sought to bring along risk-averse institutions by presenting their work as a scientifically sound approach to treating previously intractable illnesses not as a Trojan horse in the culture wars. To some ears, Doblins rhetoric about ending genocide and enlightening humanity through widespread use harkens back to Leary, the Harvard professor whose promiscuous dispensation of LSD led to his firing in 1963.
But Doblins success in bringing the fight for MDMA therapy to the cusp of fruition may go a long way toward silencing the naysayers, who have warned that potential blowback to a broad legalization effort would result in another crackdown like the one that squashed Learys early research. At least for now, those fears appear unfounded.
Im completely vindicated, Doblin said, breaking into a broad smile.
Medicalization leads to legalization because youve got fear and misinformation and people thinking that one dose, brain damage, functional consequences, addiction, stay away, he added. Theres just such decades and decades and decades of propaganda and fear. And how do you overcome that? Thats where medicalization comes in. If you can show that the benefits outweigh the risks, it causes people to start thinking.
Posted: at 6:42 am
Article content continued
This year, Canadas health minister Patty Hajdu granted 12 terminally ill Canadians Section 56 exemption to the Controlled Drug and Substances Act so they may legally access psilocybin therapy.
Earlier this month, the first non-palliative Canadian,Mona Strelaeff,was also granted an exemption.Strelaeff, 67, said she has struggled with anxiety, depression and addiction for years, but following her psilocybin treatment, her depression and anxiety seem to be gone.
For the first time, I feel like I have won the battle in my mind, she said.
Levy, who alsoco-founded CanadianCannabisClinics, a national medical cannabis access and education service, credits cannabis legalization for helping challenge perceptions and opinions about the plant, including in the medical field.
Years ago, he says, if he attended a medical conference to speak about cannabis, physicians would pass his booth with a wide berth. They would walk around and not even engage with us to avoid a conversation, he says. And within a couple of years, it changed rapidly.
Field Trips medical director, Dr. Michael Verbora, has noticed the same thing. While, five years ago, some of his colleagues worried that he might be harming his patients by giving them microdoses of THC and weaning them off anti-psychotics, he says colleagues now approach him about prescribing cannabis for a variety of conditions, even where theres a lack of supporting evidence.
So the tide has completely changed there, Dr. Verbora says. And I think its going to happen with psychedelics, as well.
He says that one of the great benefits of psychedelics is that they can introduce neuroplasticity in the brain. That really just means flexibility in the brain, he says an ability to relearn and reframe old ways of thinking.
You get this period of time, he explains, where we can rewrite some of the narratives that we tell ourselves and, perhaps, shift that into a more positive setting.